Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420914 | 0.90 | SLC6A9 (0.66) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL4425899 | 0.89 | SLC6A9 (0.72) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL5132694 | 0.88 | SLC6A9 (0.57) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL4423945 | 0.87 | SLC6A9 (0.61) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL4427344 | 0.86 | SLC6A9 (0.66) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL4419066 | 0.85 | SLC6A9 (0.62) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL5038044 | 0.85 | SLC6A9 (0.65) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL4419697 | 0.84 | SLC6A9 (0.61) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL5047636 | 0.84 | SLC6A9 (0.64) | SLC6A9SLC6A5KCNH2ENPP2LMNA | |
| SCHEMBL5045633 | 0.84 | SLC6A9 (0.61) | SLC6A9SLC6A5KCNH2ENPP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885SLC6A5 9/4885KCNH2 719/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885SLC6A5 9/4885KCNH2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.